Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostatin + Tislelizumab + Chemotherapy in Advanced NSCLC
NCT05448781Phase 2Unknown
- Sponsor
- Cancer Center of Guangzhou Medical University
- Start
- Jul 2022
- Primary completion
- Jul 2023
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of endostar in non-small cell lung cancer (NSCLC), sponsored by Cancer Center of Guangzhou Medical University. Status: unknown.
02
Drugs
endostar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05448781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05448781.